Cantor Fitzgerald Predicts ALX Oncology FY2025 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Cantor Fitzgerald issued their FY2025 EPS estimates for ALX Oncology in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($2.21) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.76) per share.

A number of other research analysts also recently issued reports on ALXO. HC Wainwright decreased their price objective on ALX Oncology from $25.00 to $5.00 and set a “buy” rating for the company in a report on Friday. Jefferies Financial Group cut shares of ALX Oncology from a “buy” rating to a “hold” rating and decreased their price target for the stock from $12.00 to $2.00 in a research note on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $3.50.

ALX Oncology Stock Down 7.1 %

ALX Oncology stock opened at $1.52 on Thursday. ALX Oncology has a twelve month low of $1.19 and a twelve month high of $17.83. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. The company has a 50 day moving average of $1.61 and a 200-day moving average of $2.42. The stock has a market capitalization of $79.90 million, a PE ratio of -0.51 and a beta of 0.98.

Insider Activity at ALX Oncology

In related news, Director Rekha Hemrajani acquired 30,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were bought at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the purchase, the director now directly owns 33,000 shares in the company, valued at approximately $51,150. This trade represents a 1,000.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders sold 14,443 shares of company stock valued at $23,309. Insiders own 33.40% of the company’s stock.

Hedge Funds Weigh In On ALX Oncology

A number of institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its position in shares of ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after acquiring an additional 6,888 shares during the period. Hsbc Holdings PLC bought a new position in ALX Oncology during the second quarter worth about $63,000. GSA Capital Partners LLP acquired a new position in ALX Oncology during the third quarter worth approximately $88,000. Barclays PLC raised its stake in ALX Oncology by 243.6% in the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock valued at $107,000 after buying an additional 42,185 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock valued at $109,000 after buying an additional 6,080 shares during the last quarter. 97.97% of the stock is currently owned by institutional investors and hedge funds.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.